Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
Background: No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide.Case Presentation: This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October...
Guardado en:
Autores principales: | Danfeng Ren, Wenya Cao, Xiaojing Liu, Qunying Han, Wanhu Fan, Guoliang Li, Han Xia, Xi Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/70ab15800e874ed78577a2321e14521b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison of Amphotericin B Lipid Complex (Abelcet) and Liposomal Amphotericin B (Ambisome) on Rat Kidney: a Morphological Evaluation
por: Mutluay,S. Deniz, et al.
Publicado: (2012) -
Comparative efficacy of amphotericin B-loaded chitosan nanoparticles and free amphotericin B drug against Leishmania tropica
por: Aamir Sohail, et al.
Publicado: (2021) -
Mucormicosis rinocerebral en un niño diabético: Tratamiento conservador
por: CHÁVEZ P,ANA, et al.
Publicado: (2004) -
Infección osteoarticular por Candida albicans
por: Chavez P,Ana, et al.
Publicado: (2000) -
Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
por: Suresh Ambati, et al.
Publicado: (2019)